{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:22:48Z","timestamp":1791501768485,"version":"4.3.4"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.bone.2021.115914","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T22:11:28Z","timestamp":1616105488000},"page":"115914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Osteogenesis imperfecta in children"],"prefix":"10.1016","volume":"148","author":[{"given":"Fawaz","family":"Arshad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2021.115914_bb0005","doi-asserted-by":"crossref","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nature reviews Disease primers"},{"key":"10.1016\/j.bone.2021.115914_bb0010","doi-asserted-by":"crossref","first-page":"E356","DOI":"10.1210\/jc.2013-3209","article-title":"Muscle anatomy and dynamic muscle function in osteogenesis imperfecta type I","volume":"99","author":"Veilleux","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.115914_bb0015","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bone.2015.05.019","article-title":"The functional muscle-bone unit in patients with osteogenesis imperfecta type I","volume":"79","author":"Veilleux","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.115914_bb0020","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00223-017-0287-y","article-title":"Muscle function in osteogenesis imperfecta type IV","volume":"101","author":"Veilleux","year":"2017","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2021.115914_bb0025","first-page":"1","article-title":"Muscle abnormalities in osteogenesis imperfecta","volume":"17","author":"Veilleux","year":"2017","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.bone.2021.115914_bb0030","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/ajmg.a.61497","article-title":"Clinical manifestations of osteogenesis imperfecta in adulthood: an integrative review of quantitative studies and case reports","volume":"182","author":"Chougui","year":"2020","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.bone.2021.115914_bb0035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s002239900600","article-title":"The mineralization density of iliac crest bone from children with osteogenesis imperfecta","volume":"64","author":"Boyde","year":"1999","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2021.115914_bb0040","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1073\/pnas.90.5.1701","article-title":"Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta","volume":"90","author":"Chipman","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bone.2021.115914_bb0045","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S8756-3282(00)00269-6","article-title":"Static and dynamic bone histomorphometry in children with osteogenesis imperfecta","volume":"26","author":"Rauch","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.115914_bb0050","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s004310051322","article-title":"Hearing loss in children with osteogenesis imperfecta","volume":"159","author":"Kuurila","year":"2000","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.bone.2021.115914_bb0055","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/BRS.0000000000003012","article-title":"Scoliosis and cardiopulmonary outcomes in Osteogenesis Imperfecta patients","volume":"44","author":"Bronheim","year":"2019","journal-title":"Spine"},{"key":"10.1016\/j.bone.2021.115914_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2017.06.004","article-title":"Splenomegaly, myeloid lineage expansion and increased osteoclastogenesis in osteogenesis imperfecta murine","volume":"103","author":"Matthews","year":"2017","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.bone.2021.115914_bb0065","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/archdischild-2017-313859","article-title":"Elevated platelet counts in a cohort of children with moderate-severe osteogenesis imperfecta suggest that inflammation is present","volume":"103","author":"Salter","year":"2018","journal-title":"Arch Dis Child"},{"issue":"10028","key":"10.1016\/j.bone.2021.115914_bb0070","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2021.115914_bb0075","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/jbmr.3424","article-title":"Mutations that alter the carboxy-terminal-propeptide cleavage site of the chains of type I procollagen are associated with a unique osteogenesis Imperfecta phenotype","volume":"33","author":"Cundy","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0080","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/humu.21475","article-title":"COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfecta","volume":"32","author":"Lindahl","year":"2011","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bone.2021.115914_bb0085","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1172\/JCI22760","article-title":"A novel COL1A1 mutation in infantile cortical hyperostosis (Caffey disease) expands the spectrum of collagen-related disorders","volume":"115","author":"Gensure","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2021.115914_bb0090","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1750-1172-8-78","article-title":"Helical mutations in type I collagen that affect the processing of the amino-propeptide result in an Osteogenesis Imperfecta\/Ehlers-Danlos syndrome overlap syndrome","volume":"8","author":"Malfait","year":"2013","journal-title":"Orphanet journal of rare diseases"},{"key":"10.1016\/j.bone.2021.115914_bb0095","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/cge.13683","article-title":"COL1-related overlap disorder: a novel connective tissue disorder incorporating the osteogenesis imperfecta\/Ehlers-Danlos syndrome overlap","volume":"97","author":"Morlino","year":"2020","journal-title":"Clin. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0100","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/ajmg.a.61100","article-title":"Cardiac valvular Ehlers-Danlos syndrome is a well-defined condition due to recessive null variants in COL1A2","volume":"179","author":"Guarnieri","year":"2019","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.bone.2021.115914_bb0105","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ajhg.2009.09.001","article-title":"PPIB mutations cause severe osteogenesis imperfecta","volume":"85","author":"van Dijk","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0110","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/ng1968","article-title":"Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal\/severe osteogenesis imperfecta","volume":"39","author":"Cabral","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0115","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1056\/NEJMoa063804","article-title":"Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta","volume":"355","author":"Barnes","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2021.115914_bb0120","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2006.08.039","article-title":"CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta","volume":"127","author":"Morello","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.bone.2021.115914_bb0125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S8756-3282(02)00790-1","article-title":"Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease","volume":"31","author":"Ward","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.115914_bb0130","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ajmg.a.36916","article-title":"CRTAP mutation in a patient with Cole-carpenter syndrome","volume":"167A","author":"Balasubramanian","year":"2015","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.bone.2021.115914_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/hmg\/dds371","article-title":"Mutations in FKBP10, which result in Bruck syndrome and recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide lysines in bone collagen","volume":"22","author":"Schwarze","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0140","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/humu.22362","article-title":"Kuskokwim syndrome, a recessive congenital contracture disorder, extends the phenotype of FKBP10 mutations","volume":"34","author":"Barnes","year":"2013","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bone.2021.115914_bb0145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ajmg.a.30231","article-title":"Phenotypic and molecular characterization of Bruck syndrome (osteogenesis imperfecta with contractures of the large joints) caused by a recessive mutation in PLOD2","volume":"131A","author":"Ha-Vinh","year":"2004","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.bone.2021.115914_bb0150","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ajhg.2010.01.034","article-title":"Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta","volume":"86","author":"Christiansen","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0155","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00223-013-9799-2","article-title":"Hyperosteoidosis and hypermineralization in the same bone: bone tissue analyses in a boy with a homozygous BMP1 mutation","volume":"93","author":"Hoyer-Kuhn","year":"2013","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2021.115914_bb0160","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ajhg.2015.04.021","article-title":"Recessive osteogenesis imperfecta caused by missense mutations in SPARC","volume":"96","author":"Mendoza-Londono","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0165","doi-asserted-by":"crossref","first-page":"11920","DOI":"10.1038\/ncomms11920","article-title":"MBTPS2 mutations cause defective regulated intramembrane proteolysis in X-linked osteogenesis imperfecta","volume":"7","author":"Lindert","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bone.2021.115914_bb0170","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/jmedgenet-2013-101567","article-title":"Mutations in WNT1 are a cause of osteogenesis imperfecta","volume":"50","author":"Fahiminiya","year":"2013","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0175","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bone.2014.06.041","article-title":"Skeletal characteristics associated with homozygous and heterozygous WNT1 mutations","volume":"67","author":"Palomo","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.115914_bb0180","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ajhg.2011.01.015","article-title":"Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta","volume":"88","author":"Becker","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0185","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/MCD.0b013e32836032f0","article-title":"Genotype-phenotype study in type V osteogenesis imperfecta","volume":"22","author":"Balasubramanian","year":"2013","journal-title":"Clin. Dysmorphol."},{"key":"10.1016\/j.bone.2021.115914_bb0190","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ajhg.2012.06.005","article-title":"A single recurrent mutation in the 5\u2019-UTR of IFITM5 causes osteogenesis imperfecta type V","volume":"91","author":"Cho","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0195","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ajhg.2012.06.011","article-title":"A mutation in the 5\u2019-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus","volume":"91","author":"Semler","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0200","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajhg.2010.05.016","article-title":"Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta","volume":"87","author":"Lapunzina","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0205","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ajhg.2014.12.027","article-title":"Cole-carpenter syndrome is caused by a heterozygous missense mutation in P4HB","volume":"96","author":"Rauch","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0210","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/jmedgenet-2012-101142","article-title":"Study of autosomal recessive osteogenesis imperfecta in Arabia reveals a novel locus defined by TMEM38B mutation","volume":"49","author":"Shaheen","year":"2012","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0215","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1750-1172-8-154","article-title":"Deficiency for the ER-stress transducer OASIS causes severe recessive osteogenesis imperfecta in humans","volume":"8","author":"Symoens","year":"2013","journal-title":"Orphanet journal of rare diseases"},{"key":"10.1016\/j.bone.2021.115914_bb0220","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ajhg.2015.01.002","article-title":"Mutations in SEC24D, encoding a component of the COPII machinery, cause a syndromic form of osteogenesis imperfecta","volume":"96","author":"Garbes","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0225","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/jmedgenet-2017-104999","article-title":"FAM46A mutations are responsible for autosomal recessive osteogenesis imperfecta","volume":"55","author":"Doyard","year":"2018","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0230","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ajhg.2020.09.009","article-title":"Interaction between KDELR2 and HSP47 as a key determinant in osteogenesis imperfecta caused by bi-allelic variants in KDELR2","volume":"107","author":"van Dijk","year":"2020","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0235","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1002\/jbmr.3233","article-title":"PLS3 deletions lead to severe spinal osteoporosis and disturbed bone matrix mineralization","volume":"32","author":"Kampe","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0240","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/ajmg.a.61366","article-title":"Nosology and classification of genetic skeletal disorders: 2019 revision","volume":"179","author":"Mortier","year":"2019","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.bone.2021.115914_bb0245","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ajhg.2013.02.010","article-title":"Mutations in WNT1 cause different forms of bone fragility","volume":"92","author":"Keupp","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0250","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ejmg.2015.11.005","article-title":"Neuroblastoma amplified sequence (NBAS) mutation in recurrent acute liver failure: confirmatory report in a sibship with very early onset, osteoporosis and developmental delay","volume":"58","author":"Capo-Chichi","year":"2015","journal-title":"European journal of medical genetics"},{"key":"10.1016\/j.bone.2021.115914_bb0255","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development","volume":"107","author":"Gong","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.bone.2021.115914_bb0260","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1359\/JBMR.050101","article-title":"Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children","volume":"20","author":"Hartikka","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0265","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ajhg.2019.08.008","article-title":"Autosomal-recessive mutations in MESD cause osteogenesis imperfecta","volume":"105","author":"Moosa","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0270","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ajhg.2015.04.017","article-title":"Homozygosity for frameshift mutations in XYLT2 result in a spondylo-ocular syndrome with bone fragility, cataracts, and hearing defects","volume":"96","author":"Munns","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0275","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/jbmr.2980","article-title":"A novel ANO5 mutation causing gnathodiaphyseal dysplasia with high bone turnover osteosclerosis","volume":"32","author":"Rolvien","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0280","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126180","article-title":"Osteoporosis and skeletal dysplasia caused by pathogenic variants in SGMS2","volume":"4","author":"Pekkinen","year":"2019","journal-title":"JCI insight"},{"key":"10.1016\/j.bone.2021.115914_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/genes10090631","article-title":"Further defining the phenotypic spectrum of B3GAT3 mutations and literature review on linkeropathy syndromes","volume":"10","author":"Ritelli","year":"2019","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.bone.2021.115914_bb0290","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/ng.252","article-title":"Gerodermia osteodysplastica is caused by mutations in SCYL1BP1, a Rab-6 interacting golgin","volume":"40","author":"Hennies","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0295","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/jmedgenet-2018-105528","article-title":"Specific combinations of biallelic POLR3A variants cause Wiedemann-Rautenstrauch syndrome","volume":"55","author":"Paolacci","year":"2018","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0300","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ajmg.a.30663","article-title":"Somatic and gonadal mosaicism in Hutchinson-Gilford progeria","volume":"135","author":"Wuyts","year":"2005","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.bone.2021.115914_bb0305","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1172\/JCI28968","article-title":"A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation","volume":"116","author":"Yang","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2021.115914_bb0310","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.bone.2010.06.004","article-title":"Skeletal phenotype of mandibuloacral dysplasia associated with mutations in ZMPSTE24","volume":"47","author":"Cunningham","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.115914_bb0315","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0320","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/ejhg.2015.81","article-title":"Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta","volume":"23","author":"Lindahl","year":"2015","journal-title":"European journal of human genetics: EJHG"},{"key":"10.1016\/j.bone.2021.115914_bb0325","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1177\/000348940211101014","article-title":"Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey","volume":"111","author":"Kuurila","year":"2002","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.bone.2021.115914_bb0330","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ajmg.a.36545","article-title":"Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment","volume":"164A","author":"Van Dijk","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.bone.2021.115914_bb0335","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2021.115914_bb0340","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/jbmr.258","article-title":"Evolution of the radiographic appearance of the metaphyses over the first year of life in type V osteogenesis imperfecta: clues to pathogenesis","volume":"26","author":"Arundel","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0345","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1359\/jbmr.070418","article-title":"Natural history of hyperplastic callus formation in osteogenesis imperfecta type V","volume":"22","author":"Cheung","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0350","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1359\/jbmr.2000.15.9.1650","article-title":"Type V osteogenesis imperfecta: a new form of brittle bone disease","volume":"15","author":"Glorieux","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0355","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.trsl.2016.11.005","article-title":"Osteogenesis imperfecta: new genes reveal novel mechanisms in bone dysplasia","volume":"181","author":"Kang","year":"2017","journal-title":"Translational research\u202f: the journal of laboratory and clinical medicine"},{"key":"10.1016\/j.bone.2021.115914_bb0360","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/jbmr.2835","article-title":"Bone material properties in Osteogenesis Imperfecta","volume":"31","author":"Bishop","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0365","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1359\/jbmr.1999.14.2.264","article-title":"The material basis for reduced mechanical properties in oim mice bones","volume":"14","author":"Camacho","year":"1999","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0370","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1042\/bj2170103","article-title":"Abnormal type I collagen metabolism by cultured fibroblasts in lethal perinatal osteogenesis imperfecta","volume":"217","author":"Bateman","year":"1984","journal-title":"Biochem. J."},{"key":"10.1016\/j.bone.2021.115914_bb0375","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.bpj.2011.11.3999","article-title":"Structural and mechanical differences between collagen homo- and heterotrimers: relevance for the molecular origin of brittle bone disease","volume":"102","author":"Chang","year":"2012","journal-title":"Biophys. J."},{"key":"10.1016\/j.bone.2021.115914_bb0380","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.bone.2012.03.007","article-title":"Ultra-structural defects cause low bone matrix stiffness despite high mineralization in osteogenesis imperfecta mice","volume":"50","author":"Vanleene","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.115914_bb0385","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/jbmr.2172","article-title":"How tough is brittle bone? Investigating osteogenesis imperfecta in mouse bone","volume":"29","author":"Carriero","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0390","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/414773a","article-title":"Bone indentation recovery time correlates with bond reforming time","volume":"414","author":"Thompson","year":"2001","journal-title":"Nature"},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2021.115914_bb0395","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3109\/03008207.2014.923860","article-title":"Multi-scale analysis of bone chemistry, morphology and mechanics in the oim model of osteogenesis imperfecta","volume":"55","author":"Bart","year":"2014","journal-title":"Connect. Tissue Res."},{"key":"10.1016\/j.bone.2021.115914_bb0400","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2013.11.023","article-title":"Mineral particle size in children with osteogenesis imperfecta type I is not increased independently of specific collagen mutations","volume":"60","author":"Fratzl-Zelman","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.115914_bb0405","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI118428","article-title":"Bone mineralization in an osteogenesis imperfecta mouse model studied by small-angle x-ray scattering","volume":"97","author":"Fratzl","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2021.115914_bb0410","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/jbmr.3071","article-title":"Diaphyseal femur fractures in Osteogenesis Imperfecta: characteristics and relationship with bisphosphonate treatment","volume":"32","author":"Trejo","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0415","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1210\/jc.2016-3745","article-title":"Bisphosphonate treatment and the characteristics of femoral fractures in children with Osteogenesis Imperfecta","volume":"102","author":"Vuorimies","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.115914_bb0420","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1093\/hmg\/ddu117","article-title":"The swaying mouse as a model of osteogenesis imperfecta caused by WNT1 mutations","volume":"23","author":"Joeng","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0425","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1172\/JCI92617","article-title":"Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasis","volume":"127","author":"Joeng","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2021.115914_bb0430","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nm.3544","article-title":"Excessive transforming growth factor-beta signaling is a common mechanism in osteogenesis imperfecta","volume":"20","author":"Grafe","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2021.115914_bb0435","doi-asserted-by":"crossref","first-page":"18813","DOI":"10.1073\/pnas.0507417102","article-title":"TGF-beta regulates the mechanical properties and composition of bone matrix","volume":"102","author":"Balooch","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bone.2021.115914_bb0440","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bone.2003.08.008","article-title":"Transforming growth factor-beta induces osteoclast formation in the absence of RANKL","volume":"34","author":"Itonaga","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.115914_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005275","article-title":"Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone","volume":"4","author":"Mohammad","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2021.115914_bb0450","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1111\/jcmm.14072","article-title":"Effect of rapamycin on bone mass and strength in the alpha2(I)-G610C mouse model of osteogenesis imperfecta","volume":"23","author":"Bateman","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bone.2021.115914_bb0455","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.038521","article-title":"Cellular stress due to impairment of collagen prolyl hydroxylation complex is rescued by the chaperone 4-phenylbutyrate","volume":"12","author":"Besio","year":"2019","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.bone.2021.115914_bb0460","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.0040007","article-title":"ER stress-mediated apoptosis in a new mouse model of osteogenesis imperfecta","volume":"4","author":"Lisse","year":"2008","journal-title":"PLoS Genet."},{"key":"10.1016\/j.bone.2021.115914_bb0465","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1136\/adc.80.6.524","article-title":"Anthropometry of patients with osteogenesis imperfecta","volume":"80","author":"Lund","year":"1999","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.bone.2021.115914_bb0470","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbrc.2018.12.111","article-title":"Endoplasmic reticulum stress is induced in growth plate hypertrophic chondrocytes in G610C mouse model of osteogenesis imperfecta","volume":"509","author":"Scheiber","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bone.2021.115914_bb0475","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1067\/mpd.2000.107892","article-title":"Osteogenesis imperfecta in childhood: prognosis for walking","volume":"137","author":"Engelbert","year":"2000","journal-title":"J. Pediatr."},{"key":"10.1016\/j.bone.2021.115914_bb0480","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/JMDH.S113483","article-title":"Managing the patient with osteogenesis imperfecta: a multidisciplinary approach","volume":"10","author":"Marr","year":"2017","journal-title":"J. Multidiscip. Healthc."},{"key":"10.1016\/j.bone.2021.115914_bb0485","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/adc.2006.106120","article-title":"Unexplained fractures in infancy: looking for fragile bones","volume":"92","author":"Bishop","year":"2007","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.bone.2021.115914_bb0490","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJMoa1106173","article-title":"Enzyme-replacement therapy in life-threatening hypophosphatasia","volume":"366","author":"Whyte","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2021.115914_bb0495","first-page":"180","article-title":"Working group on calcium M. primary hyperparathyroidism in neonates and childhood. The French experience (1984-2004)","volume":"69","author":"Mallet","year":"2008","journal-title":"Horm. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0500","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00350961","article-title":"Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta","volume":"16","author":"Devogelaer","year":"1987","journal-title":"Skelet. Radiol."},{"key":"10.1016\/j.bone.2021.115914_bb0505","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1651-2227.1998.tb01388.x","article-title":"Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta","volume":"87","author":"Astrom","year":"1998","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.bone.2021.115914_bb0510","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00005792-199707000-00005","article-title":"Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis","volume":"76","author":"Brumsen","year":"1997","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bone.2021.115914_bb0515","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2021.115914_bb0520","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/bcp.13867","article-title":"Pharmacology of bisphosphonates","volume":"85","author":"Cremers","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2021.115914_bb0525","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2021.115914_bb0530","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.bpo.0000176162.78980.ed","article-title":"Impact of alendronate on quality of life in children with osteogenesis imperfecta","volume":"25","author":"Seikaly","year":"2005","journal-title":"J. Pediatr. Orthop."},{"key":"10.1016\/j.bone.2021.115914_bb0535","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","article-title":"Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement","volume":"20","author":"Letocha","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0540","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0545","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","article-title":"Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta","volume":"21","author":"DiMeglio","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0550","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1136\/adc.2007.125468","article-title":"Two doses of pamidronate in infants with osteogenesis imperfecta","volume":"93","author":"Senthilnathan","year":"2008","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.bone.2021.115914_bb0555","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1359\/jbmr.090213","article-title":"Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"24","author":"Rauch","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0560","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1359\/jbmr.090712","article-title":"A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta","volume":"25","author":"Bishop","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0565","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.115914_bb0570","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2021.115914_bb0575","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials","volume":"30","author":"Hald","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0580","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2021.115914_bb0585","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1542\/peds.111.5.e601","article-title":"Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta","volume":"111","author":"Montpetit","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.bone.2021.115914_bb0590","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s004310000505","article-title":"Osteogenesis imperfecta: profiles of motor development as assessed by a postal questionnaire","volume":"159","author":"Engelbert","year":"2000","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.bone.2021.115914_bb0595","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jpc.13768","article-title":"Consensus guidelines on the use of bisphosphonate therapy in children and adolescents","volume":"54","author":"Simm","year":"2018","journal-title":"J. Paediatr. Child Health"},{"key":"10.1016\/j.bone.2021.115914_bb0600","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2021.115914_bb0605","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11832-011-0380-0","article-title":"Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates","volume":"6","author":"Nicolaou","year":"2012","journal-title":"J. Child. Orthop."},{"key":"10.1016\/j.bone.2021.115914_bb0610","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1359\/JBMR.040814","article-title":"Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate","volume":"19","author":"Munns","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0615","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1600-0722.2008.00529.x","article-title":"Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta","volume":"116","author":"Kamoun-Goldrat","year":"2008","journal-title":"Eur. J. Oral Sci."},{"key":"10.1016\/j.bone.2021.115914_bb0620","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00223-020-00707-1","article-title":"Bisphosphonate therapy and tooth development in children and adolescents with Osteogenesis Imperfecta","volume":"107","author":"Malmgren","year":"2020","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2021.115914_bb0625","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bone.2016.10.004","article-title":"Timing of dental development in osteogenesis imperfecta patients with and without bisphosphonate treatment","volume":"94","author":"Vuorimies","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.115914_bb0630","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00198-011-1742-7","article-title":"Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta","volume":"23","author":"Bargman","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.115914_bb0635","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","article-title":"Two years\u2019 experience with denosumab for children with osteogenesis imperfecta type VI","volume":"9","author":"Hoyer-Kuhn","year":"2014","journal-title":"Orphanet journal of rare diseases"},{"key":"10.1016\/j.bone.2021.115914_bb0640","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(14)61338-6","article-title":"Osteosclerosis induced by denosumab","volume":"385","author":"Kobayashi","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2021.115914_bb0645","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1043-2760(01)00489-1","article-title":"Osteosarcoma risk in rats using PTH 1-34","volume":"12","author":"Barbehenn","year":"2001","journal-title":"Trends Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bone.2021.115914_bb0650","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/jbmr.2776","article-title":"Sclerostin antibody treatment improves the bone phenotype of Crtap mice, a model of recessive Osteogenesis Imperfecta","volume":"31","author":"Grafe","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0655","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.10.012","article-title":"Rapidly growing Brtl\/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment","volume":"71","author":"Sinder","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.115914_bb0660","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/jbmr.3143","article-title":"BPS804 anti-Sclerostin antibody in adults with moderate Osteogenesis Imperfecta: results of a randomized phase 2a trial","volume":"32","author":"Glorieux","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115914_bb0665","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/MOP.0000000000000813","article-title":"Osteogenesis imperfecta: advancements in genetics and treatment","volume":"31","author":"Rossi","year":"2019","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.bone.2021.115914_bb0670","doi-asserted-by":"crossref","first-page":"14042","DOI":"10.1038\/boneres.2014.42","article-title":"Administration of soluble activin receptor 2B increases bone and muscle mass in a mouse model of osteogenesis imperfecta","volume":"3","author":"DiGirolamo","year":"2015","journal-title":"Bone Res"},{"key":"10.1016\/j.bone.2021.115914_bb0675","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/mus.25706","article-title":"Soluble activin receptor type IIB decoy receptor differentially impacts murine osteogenesis imperfecta muscle function","volume":"57","author":"Jeong","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bone.2021.115914_bb0680","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/jbmr.3473","article-title":"Skeletal response to soluble Activin receptor type IIB in mouse models of Osteogenesis Imperfecta","volume":"33","author":"Jeong","year":"2018","journal-title":"J. Bone Miner. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221000764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221000764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:52:01Z","timestamp":1757613121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328221000764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":136,"alternative-id":["S8756328221000764"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2021.115914","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteogenesis imperfecta in children","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2021.115914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115914"}}